Download Sample Global Peptide Antibiotics Market and Clinical Pipeline Insight 2023

“Global Peptide Antibiotics Market and Clinical Pipeline Insight 2023” report gives comprehensive insight on clinical and non-clinical parameters involved in the development and commercialization of global peptide antibiotics market. As per report findings, peptide antibiotics are expected to emerge as new growth frontier for the various stake holders involved in the research and development of antibiotics. Currently, there are 6 peptide antibiotics commercially available in the market and 24 peptide antibiotics are in clinical pipeline. With the era of “classical antibiotics” coming to an end with problems like heavy resistance to conventional antibiotics, the new era of peptide antibiotics is on its way to revolutionize the antibiotics segment. The peptide antibiotics are at the apex of new generation medications which are sure to storm the markets in the coming years.

Currently, antibiotics are the major source of revenues for the major pharmaceutical players. The demand for antibiotics is rapidly rising with many companies heavily investing in the growth of the antibiotics market. The global antibiotic demand is expected to surpass US$ 40 Billion by 2023 from less than US$ 30 Billion in 2017. However, multiple cases of antibiotic resistance have caused a concern in the healthcare industries which in turn is a major threat to the pharmaceuticals companies as it might cost them a considerable part of their revenues and profit. This situation has led to intensive research and development in the field of peptide antibiotics. The idea of a peptide antibiotic provides a one stop solution to the above issue. The inability of organisms to develop resistance against the newly developed peptide antibiotic, its increased efficacy, high specificity, decreased drug interaction, low toxicity, biological diversity and direct attacking property has made it an efficient product that could have tremendous impact in revolutionizing the new era of antibiotics.

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-peptide-antibiotics-market-and-clinical-pipeline-insight-2023.php

Table of Contents

1. Peptide Antibiotics - A New Era for Antibiotics
1.1 Introduction
1.2 Systemization of Peptide Antibiotics and Drugs
1.2.1 Non-Ribosomally Synthesized Peptide Antibiotics
1.2.2 Ribosomal Synthesized Peptide Antibiotics

2. Mechanism and Production of Peptide Antibiotics
2.1 Approach of Peptide Antibiotics on Bacterial Surface
2.2 Creational Process of Peptide Antibiotics

3. Identification of Human Antimicrobial Peptides
3.1 Human Defensins
3.2 Human Cathelicidins
3.3 Antimicrobial Neuropeptides

4. Portrayal of Peptide Antibiotics in Cancer Treatment
4.1 Introduction
4.2 Mechanism of Antimicrobial Peptides in Cancer Treatment

5. Categorization of Anticancer Peptides
5.1 Alpha-Helical Anticancer Peptides
5.2 Beta-Sheet Anticancer Peptides

6. Approved Peptide Antibiotics
6.1 Bacitracin
6.2 Viomycin

7. Market Analysis of Peptide Antibiotics
7.1 Introduction to Antibacterial Drug Market
7.2 Global Antimicrobial Peptide Market

8. Market Dynamics of Antimicrobial Peptides
8.1 Favorable Parameters
8.2 Challenges

9. Future Perspective of Peptide Antibiotics Market and Drug Development

10. Global Peptide Antibiotics Clinical Pipeline Overview
10.1 By Country
10.2 By Indication
10.3 By Mode of Action
10.4 By Formulation
10.5 By Delivery Route

11. Global Peptide Antibiotics Clinical Pipeline by Company, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-II
11.6 Phase-III
11.7 Preregistration

12. Marketed Peptide Antibiotics Clinical and Patent Analysis
12.1 Telavancin (Arbelic and Vibativ)
12.2 Dalbavancin (Dalvance and Xydalba)
12.3 Daptomycin Intravenous (Cubicin)
12.4 Oritavancin (Nuvocid and ORBACTIV)
12.5 Teicoplanin (Targocid)
12.6 Vancomycin (Vancomycin hydrochloride)

13. Competitive Landscape
13.1 AMP Therapeutics
13.2 Eli Lilly
13.3 GlaxoSmithKline
13.4 Hospira
13.5 Kasten
13.6 Madam Therapeutics
13.7 Novartis
13.8 Pacgen Life Science Corporation
13.9 Pfizer
13.10 Phosphagenics
13.11 Savara Pharmaceuticals
13.12 Theravance
13.13 Vicuron Pharmaceuticals

Figure 1-1: Structure of Some Important Peptide Antibiotics
Figure 1-2: Classification and Characterization of Peptide Antibiotics
Figure 2-1: Targets for Antimicrobial Peptides to Inhibit the Bacterial Growth
Figure 2-2: Chemical Structure of Teixobactin
Figure 2-3: Steps for the Solid Phase Synthesis of Teixobactin
Figure 3-1: Typical Processing of Cathelicidin Protein by Protease Enzymes
Figure 3-2: Mechanism of Antimicrobial Peptides in Defense against Pathogens
Figure 4-1: Angiogenesis Inhibition Mechanism of Action
Figure 6-1: Bacitracin - Mechanism of Action
Figure 7-1: Global - Antibacterial Drug Market (US$ Billion), 2016-2023
Figure 7-2: Usage of Therapeutic Peptides and Proteins in Different Disorders (%)
Figure 7-3: Global - Peptide Drug Market (US$ Billion), 2016-2023
Figure 7-4: Therapeutic Peptide Based Drugs over Route of Administration
Figure 7-5: Global - Peptide Antibiotics Clinical Pipeline by Phase (%), 2017 till 2023
Figure 7-6: Global - Peptide Antibiotics Clinical Pipeline by Phase (Number), 2017 till 2023
Figure 8-1: Favorable Parameters which Helps in the Growth of Antimicrobial Peptide
Figure 8-2: Challenges to Antimicrobial Peptide Market Growth
Figure 9-1: Different Possible Treatment Options of Cancer by Using Peptides
Figure 10-1: Global - Peptide Antibiotics Clinical Pipeline by Country (%), 2017 till 2023
Figure 10-2: Global - Peptide Antibiotics Clinical Pipeline by Indication (%), 2017 till 2023
Figure 10-3: Global - Peptide Antibiotics Clinical Pipeline by Mode of Action (%), 2017 till 2023
Figure 10-4: Global - Peptide Antibiotics Clinical Pipeline by Formulation (%), 2017 till 2023
Figure 10-5: Global - Peptide Antibiotics Clinical Pipeline by Delivery Route (%), 2017 till 2023


Table 3-1: Cell Sources of Human Defensins Antimicrobial Peptides
Table 9-1: Future Human Antimicrobial Peptides and their Proposed Targets

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.